La guía definitiva sobre edición genética.
★
Menú
Inicio Aprender Noticias Pregunta al Atlas
Explorar Tecnologías Enfermedades Tratamientos Ensayos clínicos Empresas Científicos Genes Investigación Instituciones
Más allá de la medicina Agricultura Ética Inversión Mapa mundial
Aprender y herramientas Empieza aquí Glosario A–Z Comparar tecnologías Cronología Listas y rankings Agentes de IA ★ Guardado API
Acerca de Quiénes somos Metodología Fuentes de datos Política editorial Contacto Avisos legales

🧭 Vista guiada
¿Eres nuevo en genética? Explicamos cada término mientras navegas, en un lenguaje sencillo. Las mismas páginas, con la ayuda incorporada.

⚡ Opinión experta
Ya conoces la biología. Solo el contenido — limpio y compacto, sin explicaciones adicionales. Esta es la vista predeterminada.

Idioma de la interfaz
Modo claro

Ética · Human editing

Enhancement and 'designer babies'

The question of editing for traits rather than disease — where the science is much weaker than the debate assumes.

How this page is written The Atlas does not take a position on contested ethical questions. Each page sets out the strongest version of the arguments on each side, states what is scientifically settled and what is not, and summarises the law where it exists. Where we think a claim is factually wrong — as opposed to ethically contested — we say so and cite the evidence.

La pregunta, en términos claros

'Designer babies' usually means choosing a child's intelligence, height, appearance or athletic ability. The ethical debate is serious, but it runs far ahead of the biology: traits like intelligence and height involve thousands of genetic variants each contributing a tiny amount, interacting with environment in ways nobody can predict. There is no gene to edit for these things. The realistic near-term question is narrower and more uncomfortable — the boundary between preventing disease and choosing preferences.

Enhancement editing would target traits rather than pathology. Polygenic architecture makes most desired traits inaccessible to editing: educational attainment and height involve thousands of variants of individually minute effect, with substantial gene-environment interaction and pleiotropy. Even were germline editing safe, the technical premise of trait selection by editing is largely unsupported. The practically pressing question is where disease prevention ends — deafness, achondroplasia and autism are each understood very differently by different communities.

The arguments

Qué argumentan los partidarios
  • Parents already shape children's traits through education, nutrition, medicine and environment; genetic means are not obviously different in kind.
  • A firm line between therapy and enhancement is hard to draw — vaccination enhances immunity beyond the natural baseline and is uncontroversial.
  • If a safe intervention reduced the risk of a serious late-life disease, refusing it on principle may be harder to defend than permitting it.
Qué argumentan los críticos
  • The polygenic reality means promised enhancements are largely unachievable, so the debate risks legitimising claims that cannot be delivered.
  • Selecting traits imposes one generation's preferences on people who cannot object.
  • Access would follow wealth, and heritable advantage compounds in a way no other inequality does.
  • Defining some human variations as defects to be edited out is a judgement disabled communities have consistently and forcefully rejected.
  • Pleiotropy means editing for one trait may alter others unpredictably — the same variants often do several things at once.

Where the science actually stands

Complex traits are highly polygenic. Predicting the effect of editing a small number of variants on intelligence, personality or physical performance is not currently possible, and no evidence indicates otherwise. Debate about enhancement is therefore about a capability that does not exist — which does not make the debate pointless, but does mean claims of imminent capability should be treated sceptically.

Unresolved questions

  • Where disease ends and preference begins, in conditions that communities themselves define differently.
  • Whether prohibitions could hold if the capability ever became real.
  • How to weigh reducing suffering against reducing human variation.

Sources

Written by The CRISPR Atlas editorial team Last updated Aug 25, 2026